Insider transactions

Scott M. Giacobello

CIK 1754154 · CHIEF FINANCIAL OFFICER · last filed 2026-09-18

Scott M. Giacobello is a CHIEF FINANCIAL OFFICER who has filed 27 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for WHWK, was dated Sep 18, 2026. Across all open-market trades the lifetime net is −$1.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.2M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.23M

Companies

3

Total Filings

27

Lifetime Open-Market Net

-$1.03M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
C/O WHITEHAWK THERAPEUTICS, INC.
2 HEADQUARTERS PLAZA, EAST BUILDING, 11T
MORRISTOWN, NJ 07960
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
WHWK CHIEF FINANCIAL OFFICER 333,489 $3.70 $1.23M -$890.6K 7 2026-09-18
Whitehawk Therapeutics, Inc. (AADI) Delisted CHIEF FINANCIAL OFFICER 26,750 $2.05 $54.8K -$6.6K 6 2025-03-03
GW PHARMACEUTICALS PLC (GWPH) Delisted Chief Financial Officer 161,120 $218.96 $35.28M -$131.3K 11 2021-03-04

Recent Filings

27 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-18 WHWK Grant (A) — $0 EDGAR
2026-09-15 WHWK Grant (A) — $0 EDGAR
2026-05-18 WHWK Grant (A) +38,265 $150.0K EDGAR
2026-04-17 WHWK Sell (S) −218,600 -$882.0K EDGAR
2026-04-15 WHWK Notice (144) −233,766 -$900.0K EDGAR
2026-04-03 WHWK Mixed +473,902 $0 EDGAR
2026-03-10 WHWK Mixed +4,156 -$8.6K EDGAR
2025-04-03 WHWK Grant (A) — $0 EDGAR
2025-03-03 WHWK Notice (144) −2,806 -$6.6K EDGAR
2025-03-03 Whitehawk Therapeutics, Inc. (AADI) Delisted Mixed +3,944 -$6.6K EDGAR
Showing 1–10 of 27
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.